Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial

Radiotherapy and Oncology

Volumn 126, Issue 1, 2018, Pages 177-180

  Trovo, Marco ^a   Furlan, Carlo ^a   Polesel, Jerry ^b   Fiorica, Francesco ^c   Arcangeli, Stefano ^d   Giaj Levra, Niccolò ^e   Alongi, Filippo ^e   Del Conte, Alessandro ^b   Militello, Loredana ^b   Muraro, Elena ^b   Martorelli, Debora ^b   Spazzapan, Simon ^b,e   Berretta, Massimiliano ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e Sacro Cuore Cancer Care Center Hospital   (Italy)

Author keywords

Breast cancer; Oligometastases; SBRT

Indexed keywords

CAPECITABINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTICENTER STUDY; OLIGOMETASTATIC BREAST CANCER; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; SPINAL CORD LESION; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TREATMENT RESPONSE; BREAST TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; RADIOSURGERY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 85029649123     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2017.08.032     Document Type: Article

References (16)

1. Albain, K.S., Sm, Nag, Calderillo-Ruiz, G., et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26 (2008), 3950–3957.
2. Bergh, J., Jönsson, P.E., Lidbrink, E.K., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30 (2012), 1919–1925.
3. Tawfik, H., Rostom, Y., Elghazaly, H., et al. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother Pharmacol 71 (2013), 913–919.
4. Hurvitz, S.A., Dirix, L., Kocsis, J., et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31 (2013), 1157–1163.
5. Gianni, L., Romieu, G.H., Lichinitser, M., et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31 (2013), 1719–1725.
6. Sledge, G.W., Neuberg, D., Bernardo, P., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21 (2003), 588–592.
7. Greenberg, P.A., Hortobagyi, G.N., Smith, T.l., et al. J Clin Oncol 14 (1996), 2197–2205.
8. Swain, S.A., Baselga, J., Kim, S.B., et al. N Engl J Med 372 (2015), 724–734.
9. Hellman, S., Weichselbaum, R.R., Oligometastases. J Clin Oncol 13 (1995), 8–10.
10. Alongi, F., Arcangeli, S., Filippi, A.R., et al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17 (2012), 1100–1107.
11. Scorsetti, M., Franceschin, D., De Rose, F., et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast 26 (2016), 11–17.
12. Simon, R., Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials 10 (1989), 1–10.
13. Milano, M.T., Zhang, H., Metcalfe, S.K., et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 115 (2009), 601–608.
14. Largillier, R., Ferrero, J.M., Doyen, J., et al. Prognostic factors in1,038 women with metastatic breast cancer. Ann Oncol 19 (2008), 2012–2019.
15. Finn, R.S., Martin, M., Rugo, H.S., et al. Palbociclib and letrozole in advanced breast cancer. NEJM 375 (2016), 1925–1936.
16. https://www.nrgoncology.org/Clinical-Trials/NRG-BR002.